DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

Company Overview

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company’s research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options.

Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury. The product remains investigational and has not been approved for commercial use.

DiaMedica is based in Minneapolis, Minnesota, and conducts its clinical and development activities through research collaborations and clinical studies. The company’s leadership has included Rick Pauls as president and chief executive officer. Its programs have primarily targeted patients in the United States and other regions where clinical trials are conducted.

Key Stats

• Today's Range: $7.53 to $8.10
• 50-Day Range: $6.35 to $8.42
• 52-Week Range: $5.24 to $10.42
• Volume: 260,778 shs
• Average Volume: 246,473 shs
• Market Capitalization: $408.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

DiaMedica Therapeutics Stock Analysis - MarketRank™

DiaMedica Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 711th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DiaMedica Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

DiaMedica Therapeutics has a consensus price target of $12.00, representing about 58.5% upside from its current price of $7.57.

Amount of Analyst Coverage

DiaMedica Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for DiaMedica Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DiaMedica Therapeutics is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DiaMedica Therapeutics is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DiaMedica Therapeutics has a P/B Ratio of 7.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.89% of the float of DiaMedica Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

DiaMedica Therapeutics has a short interest ratio ("days to cover") of 23.29, which indicates bearish sentiment.

Change versus previous month

Short interest in DiaMedica Therapeutics has recently increased by 1.70%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DiaMedica Therapeutics does not currently pay a dividend.

Dividend Growth

DiaMedica Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.09

News Sentiment

DiaMedica Therapeutics has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for DiaMedica Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.00% of the stock of DiaMedica Therapeutics is held by insiders.

Percentage Held by Institutions

10.12% of the stock of DiaMedica Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/17/2026
• KOL event: 10/23/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DMAC
• CIK: 1401040
• Web: www.diamedica.com
• Phone: (763) 496-5454
• Fax: N/A
• Employees: 35
• Year Founded: 2000

Price Target and Rating

• Average Price Target for DiaMedica Therapeutics: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +58.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.76%
• Return on Assets: -69.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.72
• Quick Ratio: 6.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.08 per share
• Price / Book: 7.01

Miscellaneous

• Outstanding Shares: 53,930,000
• Free Float: 51,230,000
• Market Cap: $408.25 million
• Optionable: Optionable
• Beta: 0.92